Blockade of cytotoxic T-lymphocyte antigen-4 (CTLA-4) with ipilimumab showed the first evidence of improved survival in advanced melanoma [3] and long-term survival can be achieved [3, 4]. Here, CTLA4 is linked to melanoma.